Evidence map›Paper›PMID 28049573›Full record

ReviewThe Lancet. Oncology2017

Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA.

Deborah K Mayer, Shelly Fuld Nasso, Jo Anne Earp

3 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in The Lancet. Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 190 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
190citing papers in PubMed, 13 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03690401 completednot on this mapstarted 2018, after this paper: background citation

Assessment of Body Composition in Cancer Patients Post-Treatment Using the SOZO Device

TypeobservationalSponsorPrisma Health-UpstateRan2018 to 2023Enrolled52ConditionsCancerArmsSOZO Device, DEXA Scan
NCT06067087 completednot on this mapstarted 2023, after this paper: background citation

Prognostic Understanding in Patients Receiving Enhanced Supportive Care (ProgESC Study)

TypeobservationalSponsorUniversity College, LondonRan2023 to 2024Enrolled91ConditionsAdvanced Cancer
NCT07253987 narecruitingnot on this mapstarted 2025, after this paper: background citation

Cancer Survivors Program: Effectiveness of Monitoring Adverse Events After Completion of Curative Treatment for Breast and Prostate Cancer

TypeinterventionalSponsorMasaryk Memorial Cancer InstituteRan2025 to 2026Enrolled200ConditionsProstate Cancer Patients, Breast Cancer PatientsArmsactive screening of adverse effects of anticancer therapy based on specific questionnaire + quality of life screening
3 · Its place in the literature

Who cites it

190 citing papers in PubMed, 13 syntheses or guidelines pooled it, 316 citations in OpenAlex.

  1. Cannabis use among cancer survivors: a systematic review and meta-analysis.Archives of public health = Archives belges de sante publique · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Health-related quality of life in rural cancer survivors compared with their urban counterparts: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

130 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Deborah K MayerUniversity of North Carolina School of Nursing, University of North Carolina, Chapel Hill, NC, USA; University of North Carolina Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Electronic address: dmayer@unc.edu.
Shelly Fuld NassoNational Coalition for Cancer Survivorship, Silver Spring, MD, USA.
Jo Anne EarpUniversity of North Carolina Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.
University of North Carolina at Chapel Hill · USNational Coalition for Cancer Survivorship · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
NCI NIH HHS P30 CA016086
6 · The paper itself

Abstract

More people are living after a diagnosis of cancer than ever before and now account for around 5% of the US population. The specialty of cancer survivorship has been developing and growing since the mid-1980s, but the term survivor is open to debate by people living with cancer and those caring for them. Regardless of the term used, many ongoing physical, psychological, and social needs affect quality of life for people who are living with cancer and those who have survived the disease. Survivors prefer to have these needs addressed by their oncologist but also want their primary care provider to have a role. However, survivors also believe there are communication and coordination barriers between care providers. The existing method for delivering cancer care is becoming unsustainable and is not adequately configured to deliver high-quality cancer care to this growing population in the USA, especially when confronted with projected health-care shortages by 2020. In this Series paper, we define the term cancer survivor, discuss survivors' ongoing needs and preferences for care over time, and consider the implications for delivering coordinated cancer care in the USA.

Indexed as

Needs AssessmentQuality of LifeSurvivorsHumansNeoplasmsQuality of Health Care

Identifiers

PMID28049573
OpenAlexW2567036721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.